Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:03:16 EDT Sun 06 Jul 2025
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Q:SYRE
- SPYRE THERAPEUTICS INC -
Website unknown - click to update
21:03:16 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
SYRE
- Q
2.0
15.51
·
25.36
0.2
15.76
+0.26
1.7
506.7
15.53
16.44
15.43
40.26 10.91
Jul 03
Jun 17
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Down
-- UPC Restricted:
No
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - All 0 today
More trades...
Time ET
Ex
Price
Change
Volume
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2025-06-17 07:30
U:SYRE
News Release
200
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
2025-06-16 16:05
U:SYRE
News Release
200
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025
2025-06-06 16:05
U:SYRE
News Release
200
Spyre Therapeutics Announces Grants of Inducement Awards
2025-05-28 08:30
U:SYRE
News Release
200
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
2025-05-08 16:05
U:SYRE
News Release
200
Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
2025-05-05 08:00
U:SYRE
News Release
200
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001
2025-05-02 16:05
U:SYRE
News Release
200
Spyre Therapeutics Announces Grants of Inducement Awards
2025-04-04 16:05
U:SYRE
News Release
200
Spyre Therapeutics Announces Grants of Inducement Awards
2025-03-27 16:05
U:SYRE
News Release
200
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
2025-03-07 16:40
U:SYRE
News Release
200
Spyre Therapeutics Announces Grants of Inducement Awards
2025-02-27 16:05
U:SYRE
News Release
200
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
2025-02-25 08:00
U:SYRE
News Release
200
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
2025-02-19 08:00
U:SYRE
News Release
200
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
2025-02-07 17:13
U:SYRE
News Release
200
Spyre Therapeutics Announces Grants of Inducement Awards
2025-01-13 08:00
U:SYRE
News Release
200
Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts
2025-01-03 17:20
U:SYRE
News Release
200
Spyre Therapeutics Announces Grants of Inducement Awards
2024-12-18 08:00
U:SYRE
News Release
200
Spyre Therapeutics Added to the Nasdaq Biotechnology Index
2024-12-02 17:03
U:SYRE
News Release
200
Spyre Therapeutics Announces Grants of Inducement Awards
2024-12-02 08:00
U:SYRE
News Release
200
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
2024-11-25 17:11
U:SYRE
News Release
200
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference